Loading...
Loading...
MIRA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 3,160.1K |
| Operating I/L | -3,160.1K |
| Other Income/Expense | -427.7K |
| Interest Income | 0.0K |
| Pretax | -3,587.8K |
| Income Tax Expense | -3.2K |
| Net Income/Loss | -3,587.8K |
MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company specializing in the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog, MIRA1a, for the treatment of anxiety and cognitive decline in early-stage dementia patients. The company's focus is on developing synthetic cannabinoid analogs to target cannabinoid type 1 and type 2 receptors for the treatment of anxiety and chronic pain in adult patients.
